NCT04562389 2025-10-03
SENTRY
Karyopharm Therapeutics Inc
Phase 3 Active not recruiting
Clinical Trials
4 trialsNCT04551053 2025-10-02
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
Incyte Corporation
Phase 3 Terminated
NCT04472598 2025-02-21
TRANSFORM-1
AbbVie
Phase 3 Completed
NCT00952289 2018-03-12
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Incyte Corporation
Phase 3 Completed